Drug Profile
Lipovaxin MM - Lipotek
Alternative Names: 2401502; GSK-2401502; Lipovaxin-MMLatest Information Update: 16 Aug 2023
Price :
$50
*
At a glance
- Originator Lipotek
- Developer GSK; Lipotek
- Class Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Malignant-melanoma in Australia (IV, Infusion)
- 26 Apr 2016 Phase I development is ongoing in Australia
- 01 Mar 2012 Lipotek completes a phase I trial in Malignant melanoma in Australia (NCT01052142)